Inozyme Pharma, Inc.
Inozyme Pharma, Inc. (INZY): 2 pipeline candidates · ~9 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.7 months
D/E 1.99 · 0% dilution
Lead: Phase 3
2 candidates
N/A
N/A
A transparent, data-derived signal for Inozyme Pharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$25.8M
Quarterly Burn
$29.1M
Runway
8.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| cin-102 dose 15mg or | Phase 2 |
| inz-701 | Phase 3 |
Frequently asked questions
How many drug candidates are in Inozyme Pharma, Inc.'s pipeline?
Inozyme Pharma, Inc. (INZY) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Inozyme Pharma, Inc.'s lead drug candidate?
Inozyme Pharma, Inc.'s most advanced tracked candidate is cin-102 dose 15mg or (Phase 2) for Diabetic Gastroparesis.
What is Inozyme Pharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Inozyme Pharma, Inc. has approximately 8.7 months of cash runway.
Who is the CEO of Inozyme Pharma, Inc.?
Douglas A. Treco, Ph.D. is the chief executive officer of Inozyme Pharma, Inc. (INZY).
Get the full picture on Inozyme Pharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.